Europe asks UK to reject cloning approval …

A New Approach to Psychiatric Drug Approval in Europe

Corrado Barbui and Irene Bighelli question the current rules governing registration of new medicines in Europe, using the example of psychiatric drugs, and argue that the concept of absolute efficacy should be replaced by the concept of added value whereby evidence from studies comparing a new product with an active comparator should guide the drug approval process. Please see later in the arti...

Europe grapples with cloning headaches

The growing spectre of human reproductive cloning is putting unprecedented strain on some of the legislative bodies in Europe trying to keep a grip on it and the future of embryonic stem cell research. In Britain, which has gone further than many countries with detailed legislation to permit research on embryonic stem cells, a group of opponents late last year challenged the legislation, saying...

PEI asks residents how to improve health.

To protect or reject

A protein known for its role in dismantling faulty SNARE complexes can also help to maintain complexes that have formed properly during membrane fusion.

Approval of the first biosimilar antibodies in Europe

In a defining moment for the European Medicines Agency (EMA) and the biopharmaceutical industry, on June 27, 2013 EMA's Committee for Medicinal Products for Human Use adopted a positive opinion for two biosimilar infliximab products (Celltrion's Remsima® and Hospira's Inflectra®), and recommended that they be approved for marketing in the European Union (EU). The European Commission's decision ...